Karuna Therapeutics, Inc.
KRTXDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Nov 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
KarXT | Phase 3 | Schizophrenia | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Karuna Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Karuna Therapeutics, Inc.'s (KRTX) pipeline across Phase 3. Its lead program is Xanomeline and Trospium Chloride Capsules (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Karuna Therapeutics, Inc.'s next FDA catalyst?→
Karuna Therapeutics, Inc.'s (KRTX) next tracked catalyst is a Phase 3 expected November 24, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track KRTX biotech catalysts?→
Add KRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Karuna Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.